Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
1992
|
| gptkbp:approvedBy |
gptkb:United_States
|
| gptkbp:ATCCode |
gptkb:C08CA01
|
| gptkbp:bioavailability |
60-65%
|
| gptkbp:CASNumber |
gptkb:88150-42-9
|
| gptkbp:chemicalFormula |
C20H25ClN2O5
|
| gptkbp:contraindication |
severe hypotension
allergy to amlodipine |
| gptkbp:drugClass |
gptkb:beta_blocker
|
| gptkbp:eliminationHalfLife |
30-50 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
10 mg
5 mg 2.5 mg |
| gptkbp:genericName |
gptkb:amlodipine
|
| gptkbp:halfLife |
30-50 hours
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
edema
dizziness palpitations flushing |
| gptkbp:usedFor |
gptkb:angina
hypertension |
| gptkbp:bfsParent |
gptkb:amlodipine
gptkb:Pfizer_(2000) |
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Norvasc
|